Kadimastem
Business Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7 Pinhas Sapir, Ness Ziona, Central Dist...Phone Number
+972 737971600Website
www.kadimastem.comRevenue
<$5 MillionIndustry
About Kadimastem
Kadimastem Org Chart
Is Kadimastem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Kadimastem launches new products
Website visits: Recent activity has been detected on your website
Check if Kadimastem has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kadimastem has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kadimastem is spiking on competitors!
Click to see if Kadimastem had a recent Job posting/layoffs
Kadimastem, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Kadimastem recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Kadimastem
Recommended Actions
Reach out to Masked Content who joined Kadimastem as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Kadimastem is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kadimastem is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kadimastem.
Kadimastem Tech Stack
A closer look at the technologies used by Kadimastem
Kadimastem News & Media
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL" ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger...NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a...NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that, following the receipt of Nasdaq's approval for the listing of the Company's...
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kadimastem
Kadimastem is a clinical stage biotechnology company based in Israel, specializing in regenerative medicine and cell therapy. The company focuses on developing innovative treatments for incurable diseases, including diabetes and ALS, using a unique platform for off-the-shelf cell-based products. Kadimastem aims to become a global leader in cell the... Read More